GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MTech Mobility Appoints Rodney Moore as General Manager, Europe, to Accelerate Regional Growth15.9.2026 12:00:00 CEST | Press release
Seasoned technology executive brings more than 30 years of enterprise IT leadership to Dublin as MTech Mobility deepens its European commitment following Aer Lingus implementation win DUBLIN, IRELAND / ACCESS Newswire / September 15, 2026 / MTech Mobility today announced the appointment of Rodney Moore as General Manager, Europe. Moore, based in Dublin, will lead MTech Mobility's European operations, expand the regional team, and serve as the primary point of contact for the company's growing base of European customers. "Our European customers face challenges that demand more than a remote relationship - they need a partner who is present, accountable, and embedded in their landscape. Rodney's appointment is a direct investment in that commitment. His track record across Ireland and the UK means he understands exactly what European enterprises face, and he has the depth of experience to help them solve it. We are not just expanding our footprint; we are building the kind of trusted par
Chervon Names Matthew H. DeFeo as Senior Vice President of Sales, Training and Recruiting15.9.2026 00:00:00 CEST | Press release
Accomplished Power Tools and Outdoor Power Equipment industry leader brings decades of experience in sales leadership, talent recruitment and development, channel management, and key account alignment NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Matthew DeFeo joins Chervon as Senior Vice President of Sales, Training, and Recruiting effective September 14, 2026, reporting to CEO Joe Galli. Matthew DeFeo brings more than four decades of experience in the power tool and outdoor power equipment industry. He has an exceptional track record in building and leading large sales organizations, channel marketing teams, and training and development teams. DeFeo is widely recognized as a world-class leader in the campus recruiting of high potential graduates. He has built out impressive in-store sales coverage teams, end user marketing teams, campus recruiting teams, and training teams with an intense focus on key account alignment. A hallmark of DeFeo's remarkable career is his mentors
Chervon Names Jeffrey P. Campbell Senior Vice President of Industrial Commercial Sales14.9.2026 23:50:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Jeffrey P. Campbell joins Chervon as Senior Vice President of Industrial Commercial Sales effective Monday, September 14, 2026, reporting to CEO Joe Galli. Campbell joins Chervon with 25 years of exceptional executive leadership experience in the professional tool industry. He has built and led high-performance sales and channel marketing teams, developed strategic key account partnerships and has consistently driven strong growth across all professional and automotive channels of distribution. In his new role, Campbell will lead Chervon's Industrial / Commercial Sales network serving the many professional and automotive tool channels. "Jeff brings an impressive and unmatched combination of professional and automotive channel sales leadership, channel management, customer partnership skills and organizational development," said Joe Galli, CEO of Chervon. "His exhaustive command of our channels, key accounts, and users, combined wi
AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 202614.9.2026 16:30:00 CEST | Press release
One unified Enterprise Imaging platform brings workflow, streaming, cloud, and AI together to help clinicians stay focused and imaging organizations reduce complexity. CARLSTADT, NJ / ACCESS Newswire / September 14, 2026 / "Clinical attention has become one of healthcare's most valuable resources. The technology surrounding clinicians should preserve focus, not compete for it," said Nathalie McCaughley, President, AGFA HealthCare. "At RSNA 2026, we're showing how Enterprise Imaging continues to evolve around one consistent clinical experience. By bringing workflow, intelligence, and information together around how clinicians naturally work, we can reduce friction and help keep clinical attention where it matters most." At RSNA 2026, AGFA HealthCare will demonstrate how a unified approach to Enterprise Imaging can help healthcare organizations address a growing challenge: imaging volumes and clinical complexity continue to increase, while radiologists and imaging teams are being asked t
Litum Expands PathAware from Collision Warning to Forklift Safety Intelligence14.9.2026 08:00:00 CEST | Press release
PathAware® now turns collision risks, near misses and operator activity into actionable safety intelligence, while adding operator control, digital inspections and utilization insights, all through a retrofit system built for mixed forklift fleets. BOSTON, MA / ACCESS Newswire / September 14, 2026 / Litum today announced PathAware® IQ and PathAware® IQ+, expanding its forklift collision warning technology into a connected safety intelligence platform. PathAware IQ not only warns operators when risks occur. It captures safety events across the fleet and turns them into visual dashboards and actionable data, giving safety teams visibility into recurring risks, near misses, operators, vehicles, areas and shifts. This allows organizations to move from reacting to incidents to identifying patterns earlier, targeting operator training, addressing recurring hazards and measuring whether safety actions are actually working. PathAware IQ+ builds on that intelligence with digital pre-operation i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom